177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J. Morris, Daniel Castellano(Hospital Universitario 12 De Octubre), Ken Herrmann, Johann S. de Bono(Royal Marsden Hospital), Neal D. Shore(Carolina Urologic Research Center), Kim N., Michael J. Crosby(Health Awareness (United States)), Josep M. Piulats(Institut Català d'Ornitologia), Aude Fléchon(Centre Léon Bérard), Xiao X. Wei(Dana-Farber Cancer Institute), Hakim Mahammedi(Centre Jean Perrin), Guilhem Roubaud(Institut Bergonié), Hana Študentová(University Hospital Olomouc), James Nagarajah, Begoña Mellado(Universitat de Barcelona), Álvaro Montesa-Pino(Hospital Regional Universitario de Málaga), Euloge Kpamegan(Novartis (United States)), Samson Ghebremariam(Novartis (United States)), Teri Kreisl(Novartis (United States)), Celine Wilke(Novartis (Switzerland)), Katja Lehnhoff(Novartis (Switzerland)), Oliver Sartor(Mayo Clinic in Arizona), Karim Fizazi(Institut Gustave Roussy)
Cited by 245Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis